BioCentury
ARTICLE | Emerging Company Profile

Freshening the gene pool

How Horama is differentiating itself in ophthalmic gene therapy

June 15, 2015 7:00 AM UTC

Horama S.A.S. is developing two gene therapies that target mutations no other companies are working on as a way of differentiating itself from the growing fraternity of ophthalmic gene therapy companies.

The company was founded in 2014 with licenses to a portfolio of recombinant adeno-associated virus (rAAV) technologies from the Institut National de la Santé et de la Recherche Médicale (INSERM), AFM-Téléthon, University Hospital of Nantes and University Hospital of Montpellier...